Mgc Pharmaceuticals Share Discussion Threads

[cal57] 11/4/2023 11:21

Ye thanks for the reminder.

[heatseek77] 11/4/2023 11:08

cal it already has funds mercer they are just releasing the £ as and when they need it

[cal57] 11/4/2023 10:38

Ye dropped it below the placing price now.Seems that all the good news is negated by the continual need to raise funds.

[kenbos] 11/4/2023 10:19

Market doesn't see it like that cal

[cal57] 11/4/2023 07:46

This is very good news MGC Pharmaceuticals Limited11 April 2023MGC Pharmaceuticals Ltd.CannEpil(R) now available by Named Patient Request in UK11 April 2023ASX, LSE: MXCHighlights:-- CannEpil(R) , MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.-- The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists .-- The availability via Named Patient Request follows the announcement [1] that MGC Pharma is providing CannEpil(R) to an observational trial supported by the I am Billy Foundation.

[cal57] 11/4/2023 06:50

11 April 2023Via email: [e-mail] Sir/MadamThe Directors of MGC Pharmaceuticals Ltd (the "Company") request that the Company's securities be placed in a voluntary trading halt with immediate effect, in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company pursuant to the completion of a capital raising in the United Kingdom and Australia.The Company requests that the trading halt end on the earlier of the commencement of normal trading on Thursday 13 April 2023, or when the announcement referred to above is released to the market on completion of both the offer in Australia, and the Broker Option offer to retail investors in the United Kingdom.The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

[sloppyjoe2] 06/4/2023 09:41

Good volume, for so early in the day...

[sloppyjoe2] 03/4/2023 19:10

"The pharmaceuticals stock has a growing patient base in Australia, the UK, Brazil and Ireland, while its commercial partners and global distriabution footprint mean it is poised to supply leading pharmaceutical markets like the US and Europe."Sounds good to me - IF they deliver on the promise...

[sloppyjoe2] 03/4/2023 16:35

Depending obviously on how the research goes, this could be very exciting in a few years...

[mam fach] 03/4/2023 13:18

This will be good for holders mental health!
Not the product but seeing share price rise.
WE can but dream.

[sloppyjoe2] 03/4/2023 12:12

If this news flow keeps up we might even get to 1p sooner rather than later... Need some more OTC approvals in large markets...

[sloppyjoe2] 03/4/2023 12:04

I wonder if shareholders will get a discount? ??

[sloppyjoe2] 03/4/2023 12:03

Pillow - in my youth I did lots of unofficial research ??

[sloppyjoe2] 03/4/2023 12:03

Lawson - you seem like a pretty fungi... ??

[pillow] 03/4/2023 11:02

I would imagine most shareholders would willingly take part in human trials for this.

[flc] 03/4/2023 10:57

Creeping back slowly now :-)

[lawson27] 03/4/2023 10:55

According to agaric this could fly on this magic news, should see the share price mushroom from here ;-))

[sloppyjoe2] 03/4/2023 10:46

Research suggesting small doses of psilocybin are an effective treatment for depression. Very interesting news...

[looneytune] 02/4/2023 23:48

3 April 2023 ASX Code: MXC LSE Code: MXC
MGC Pharma receive permission to Develop and Research new medicines with Psilocybin
Highlights:
• MGC Pharma have received permission from The Slovenian Ministry of Health to undergo research with Psilocybin.
• Psilocybin is a psychedelic compound that naturally occurs in a variety of fungi.
• MGC Pharma have permission to develop and research analytical methods, to research and
develop new drug formulations and research of properties of the drug.
• MGC Pharma can now provide development and compounding services to companies dealing
with Psilocybin and wish to have a medicine in the market.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has received permission from the Slovenian Ministry of Health to undergo scientific research development on the psychedelic compound Psilocybin.
The permission granted covers the development of analytical methods, research of physical-chemical properties of Psilocybin and development of pharmaceutical forms that would be suitable for administration.
Psilocybin is a naturally occurring psychedelic compound found in a variety of fungi and mushrooms which shows great potential in many serious medical conditions.
MGC Pharma is one of the first companies to obtain permission to undertake pharmaceutical research on Psilocybin and the first in Slovenia. The company plans to work with other pharmaceutical businesses to collaborate and provide research capabiliti